Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immuneering Corp IMRX

Healthcare Biotechnology
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve... see more

Recent & Breaking News (NDAQ:IMRX)

Immuneering To Present at Guggenheim 2023 Oncology Conference

GlobeNewswire January 31, 2023

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

GlobeNewswire November 28, 2022

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

GlobeNewswire November 10, 2022

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

GlobeNewswire November 10, 2022

Immuneering Announces Participation in November Investor Conferences

GlobeNewswire November 3, 2022

Immuneering Appoints Leah R. Neufeld as Chief People Officer

GlobeNewswire October 20, 2022

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 5, 2022

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

GlobeNewswire September 30, 2022

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

GlobeNewswire September 2, 2022

Immuneering Announces Participation in September Investor Conferences

GlobeNewswire August 25, 2022

Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights 

GlobeNewswire August 10, 2022

Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

GlobeNewswire July 6, 2022

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

GlobeNewswire May 26, 2022

Immuneering Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 20, 2022

Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights 

GlobeNewswire May 10, 2022

Immuneering Announces Participation in Citi's Biopharma VIRTUAL Co-Panel Day

GlobeNewswire May 5, 2022

Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference

GlobeNewswire April 1, 2022

Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire March 24, 2022

Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

GlobeNewswire March 10, 2022

Immuneering Announces Participation in March Investor Conferences

GlobeNewswire February 24, 2022